A UK cost–effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers

Abstract

Background: The current work was designed to estimate the cost-effectiveness of trifluridine/tipiracil (T/T) versus best supportive care (BSC) for patients with advanced stage or metastatic gastroesophageal cancer (mGC) from a UK perspective.

Materials & methods: A partitioned survival analysis was undertaken using data from the phase III TAGS trial. A jointly fitted lognormal model was selected for overall survival and individual generalized gamma models were chosen for progression-free survival and time-to-treatment-discontinuation. The primary outcome was the cost per quality-adjusted life year (QALY) gained. Sensitivity analyses were undertaken to investigate uncertainty.

Results: Compared with BSC, T/T was associated with a cost per QALY gained of £37,907.

Conclusion: T/T provides a cost-effective treatment option for mGC in the UK setting.

Metadata

Item Type:	Article
Authors/Creators:	Hamerton, L. Gomes, K. Fougeray, R. Hook, E.S. https://orcid.org/0000-0002-6503-2850 Gomes, M.V. Hauch, O. https://orcid.org/0000-0002-0026-8301 Bullement, A. https://orcid.org/0000-0001-7091-0972
Copyright, Publisher and Additional Information:	© 2023 The Authors. This work is licensed under the http://creativecommons.org/licenses/by-nc-nd/4.0/ Attribution-NonCommercial-NoDerivatives 4.0 Unported License
Keywords:	Scotland; chemotherapy; cost–effectiveness analysis; gastrointestinal/esophageal; health economics; health technology assessment; trifluridine/tipiracil; Humans; Trifluridine; Uracil; Cost-Effectiveness Analysis; Cost-Benefit Analysis; Thymine; Stomach Neoplasms; Pyrrolidines; Esophageal Neoplasms; Neoplasms, Second Primary; United Kingdom; Colorectal Neoplasms; Antineoplastic Combined Chemotherapy Protocols
Dates:	Published: 28 April 2023 Published (online): 28 April 2023 Accepted: 2 March 2022
Institution:	The University of Sheffield
Academic Units:	The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > ScHARR - Sheffield Centre for Health and Related Research
Depositing User:	Symplectic Sheffield
Date Deposited:	08 Aug 2024 13:40
Last Modified:	08 Aug 2024 13:40
Status:	Published
Publisher:	Informa UK Limited
Refereed:	Yes
Identification Number:	10.2217/fon-2022-0662
Related URLs:	PubMed URL
Sustainable Development Goals:
Open Archives Initiative ID (OAI ID):	oai:eprints.whiterose.ac.uk:215761

CORE (COnnecting REpositories)

A UK cost–effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers

Abstract

Metadata

Download

Published Version

Export

Statistics